Home › Mercks KEYTRUDA (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1
 

Keywords :   


Mercks KEYTRUDA (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1

2015-12-19 16:55:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KEYNOTE-010 Published in The Lancet and to be Presented at the European Society for Medical Oncology (ESMO) Asia 2015 Congress KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy compared to chemotherapy based on prospective measurement of PD-L1 expression in patients with advanced non-small cell lung cancer (NSCLC). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of level express cell

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05Croda Beauty Launches New Ceramide Range
16.05Doves New Bond Strength Range Contains Proprietary Bio-Protein Care and Peptides
16.05Mount Sinai Awarded $6.6 Million from National Institutes of Health to Investigate Treatment ...
16.05Eastern North Pacific Tropical Weather Outlook
16.05Amherst Label adds third Domino press
16.05Atlantic Tropical Weather Outlook
16.05Simply.TV provides metadata to Drei TV Austria
16.05Backlash as Morrisons trials sale of New Zealand lamb
More »